Premium
Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy
Author(s) -
Watanabe Tsunamasa,
Tanaka Yasuhito
Publication year - 2013
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12014
Subject(s) - medicine , rituximab , immunology , hepatitis b virus , fulminant hepatitis , hepatitis c virus , fulminant , virology , antibody , chemotherapy , hepatitis b , antigen , hepatitis , virus
Reactivation of hepatitis B virus ( HBV ) or hepatitis C virus ( HCV ) infection following anticancer chemotherapy and immunosuppressive therapy is a well‐known complication. HBV reactivation has been reported to be associated with anti‐ CD 20 monoclonal antibody rituximab‐containing chemotherapy and tumor necrosis factor‐α inhibitor‐containing immunosuppressive therapy in HBV resolved patients (hepatitis B surface antigen negative and antibodies against hepatitis B core antigen positive and/or antibodies against surface antigen positive). On the other hand, HCV reactivation has been reported to be associated with liver damage or hepatic dysfunction, but fulminant hepatitis due to HCV reactivation is a rare complication. In this review, we describe the pathophysiology of the reactivation of HBV and HCV infection, as well as the clinical evidence and management of HCV reactivation.